Nakom Mite (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, replenishing deficient neurotransmitter levels. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the brain and reducing peripheral side effects.

The appropriate dose of Nakom Mite is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made according to therapeutic response and side‑effect profile.

Safety of levodopa/carbidopa in pregnancy and lactation has not been established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Nakom Mite, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levodopa/carbidopa remains the most effective symptomatic therapy for Parkinson’s disease. Compared with dopamine agonists or MAO‑B inhibitors, it typically provides greater motor improvement but may have a higher incidence of motor complications such as dyskinesia, which are managed through dosing strategies.

Nakom Mite should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nakom Mite is taken orally, usually with a small amount of water. It may be administered with or without food, but high‑protein meals can interfere with absorption, so consistent timing relative to meals is recommended.

Serious risks include the development of dyskinesia, severe orthostatic hypotension, psychiatric disturbances such as hallucinations, and rare events like neuroleptic malignant syndrome. Patients should be monitored regularly for these complications, especially after dose changes.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors, and caution is advised in those with severe cardiovascular disease, narrow‑angle glaucoma, or uncontrolled hypertension.